



Spain: Manuel Pombo Angulo, 28 • 28050 MADRID - Spain • Phone: +34 91 302 15 60 • Fax: +34 91 766 89 63 madrid@chemogroup.com

Switzerland: Via F. Pelli, 17 • 6901 Lugano - Switzerland • Phone: +41 91 973 21 01 • Fax: +41 91 973 21 06 lugano@chemogroup.com

Argentina: Edificio INSUD, Paraguay 1535 • C1061ABC w- Buenos Aires • Capital Federal - Argentina • Phone: +54 11 4872 1100 • Fax: +54 11 4872 12001 info@grupoinsud.com

www.chemogroup.com

WE TRANSFORM REALITY

TOGETHER





INNOVATION TO KEEP GROWING

COMMITTED TO HIGH-QUALITY MANUFACTURING

STEP AHEAD SOLUTIONS

RETHINKING HEALTHCARE

BIOSIMILAR MEDICINES OF THE FUTURE

TRANSCENDING BORDERS



CHEMO

IT IS TIME
TO CHANGE
THE RULES

INNOVATION TO KEEP GROWING

More than 6.000 professionals
in over 40 countries, across 5 continents.

Founded in 1977, CHEMO operates across
the entire pharmaceutical value chain,
delivering specialized expertise in scientific
research, development, manufacturing, sales
and marketing of a wide range of active
pharmaceutical ingredients (APIs), finished
dosage forms (FDFs) and branded
pharmaceuticals, for human and animal care.

While the main offices are located in Madrid,
Lugano and Buenos Aires, CHEMO is present
worldwide, creating a broad and balanced
manufacturing and commercial network
across the five continents to address global
opportunities and customers' needs in all
major pharmaceutical markets.

9 specialized
R&D centers


11 state
-of-the-
art
facilities

Over
35 pharmaceutical
affiliates

1.150
customers in
96 countries

12 commercial
offices






CHEMO GROUP

WE EXTEND OUR PASSION TO
ALL CORNERS OF THE WORLD

Argentina	Lithuania
Austria	Luxembourg
Azerbaijan	Malaysia
Belgium	Mexico
Brazil	Morocco
Chile	Nicaragua
China	Panamá
Costa Rica	Paraguay
Czech Republic	Philippines
Dominican Republic	Poland
El Salvador	Portugal
Estonia	Russia
France	Singapore
Georgia	Slovakia
Germany	Spain
Guatemala	Switzerland
Honduras	The Netherlands
Hungary	Thailand
Indonesia	Turkey
India	Ukraine
Italy	United States
Kazajistan	Uruguay
Latvia	Vietnam



COMMITTED TO HIGH - QUALITY MANUFACTURING



World-leading position researching, developing and manufacturing more than 100 value-added active pharmaceutical ingredients and over 50 medicines with more than 200 different product presentations with own APIs production and own formulation patents for all major therapeutic areas.

CHEMO's facilities include 4 chemical plants in Italy, Spain, Argentina and India and 2 pharmaceutical installations in Spain, all fully compliant with GMP regulations, and FDA and EMA quality standards with cutting-edge technologies, highly qualified professionals, strict safety standards, and the most up-to-date equipment to perform a wide variety of chemical reactions and manufacture a full range of dosage forms.

Coordinated by our headquarters, the company is involved in wide commercial activity through its 12 offices, serving 1.115 customers in 96 countries around the word, always committed to an active engagement with customers and to provide value to our business relationships.

Partner of choice
in the entire
pharmaceutical
value chain

Facilities
with cutting-edge
technologies
and great
capacities

A strong
and worldwide
commercial
network



INDUSTRIAL ACTIVITY

ANIMAL HEALTHCARE

CHEMO, through its company Vetpharma, focused on animal healthcare, is engaged in the registration and commercialization of active principles, intended for the manufacturing of phytosanitary and animal health products; veterinary generic medicines in oral and injectable form for poultry, porcine, bovine, ovine and companion animals; and feed additives for animal nutrition with therapeutic effects (nutraceuticals).

Over 20 products registered in more than 25 countries

High quality nutraceuticals



OTC

Our OTC division designs, develops, manufactures, and packs food supplements combining all our experience and know-how with the flexibility and proactivity required by this category. We have a food supplements area equipped with the latest technology and within our pharmaceutical plants.

There, we develop tailor-made solutions or ready to market formulas in different forms, including soft gel capsules, hard capsules, tablets, pellets, sachets and cosmetics.

Food Supplements for health

Pharmaceutical quality standards

STEP AHEAD SOLUTIONS



Innovation is a key driver of sustainable growth in CHEMO. The company has a strong commitment to invest in R&D to develop new pharmaceutical products, optimize manufacturing processes and ensure a dynamic and useful portfolio for all customers.

Our commitment with innovation and constant growing, is shown by the construction of our two new manufacturing facilities in Spain that will provide injectable capabilities with the most updated technology and highest quality standards.




CHEMO's own integrated research and development network comprises 9 specialized R&D centers in Spain, Italy, Argentina, China and India, with cutting-edge technologies, most up to date analytical instrumentation and over 200 highly qualified scientists, as well as collaborations with significant pharmaceutical partners and top academic institutions worldwide.

Over
50 projects
in our R&D
pipeline

Research focused
on new drugs and
active pharmaceutical
ingredients in
all major lines
of therapy

Expanding
in the injectables
area through two
new manufacturing
plants

RETHINKING HEALTHCARE



Strong position in Women's Health

Growing presence in different therapeutic areas

Worldwide manufacturing and commercial network



Through our branded business, Exeltis, we provide patients and healthcare professionals with a balanced catalogue of over 300 products accessible in all continents. This wide and varied range includes products for some of the most important therapeutic areas, such as Women's Health, Respiratory, Dermatology and Endocrinology, among others.

With a strong position in the Women's Health sector, Exeltis accompanies women in all phases of their lives and offers them a variety of gynaecological products adapted to their needs.

Exeltis has a presence in more than 40 countries in Europe, America, Asia and Africa, through more than 35 pharmaceutical affiliates and a global network of over 2.000 sales representatives.



BIOSIMILAR MEDICINES OF THE FUTURE



With more than 100 professionals in different countries, our biopharmaceutical company mAbxience is engaged in the research, development, and manufacturing of biologic products, mainly biosimilar drugs for the treatment and prevention of diseases in different therapeutic areas.

Through the development of biosimilars mAbxience facilitates accessible therapies to a larger number of patients.

mAbxience works to ensure that each product is similar to the original, with the same genetic fidelity, and with the precision of a human fingerprint. "Fingerprint-like, biosimilars by design" is our work methodology.

For the development of biosimilars, mAbxience has the most advanced and sophisticated equipment. Our Buenos Aires facility became the first in South America to produce mAbs using Single-use technology. Besides our plant in Leon (Spain) is our European R&D center of monoclonal antibodies and one of the main biopharmaceutical development plants in Europe, with fully integrated Single-Use technology. In addition, Sinergium Biotech in Buenos Aires is our strategic partner for finishing highly complex biopharmaceuticals.



**Fingerprint-like
Biosimilars by design**



**Three impact
areas: autoimmune
diseases, oncology
and hematology**

**First plant
in Europe
to implement
Single-Use
technology**

**Fully committed
to high-quality
products
and accessible
therapies**





Promoting
public-private
relationships
to help the
most needed

Leading
high impact
healthcare
projects

Over 20 years
working against
neglected
diseases

TRANSCENDING BORDERS

Mundo Sano is a non – profit organization supported by CHEMO devoted to prevent and eradicate transmissible diseases like Chagas, Dengue fever, Leishmaniasis or Hidatidosis, the so-called “Neglected Tropical Diseases”, which especially affect the most vulnerable, causing serious health consequences.

Since its inception in 1993, Mundo Sano has been developing and managing intervention models with public-private collaboration, based on technology transfer to the communities affected and in the most socially endemic areas. Today, Mundo Sano is internationally recognized as a leading organization in this field.

Mundo Sano undertakes community action and research mainly in Argentina, Spain and Ethiopia.

In addition, Mundo Sano has coordinated a scientific, manufacturing and commercial effort to launch a needed medicine against Chagas disease, now available in Argentina and Spain.

